The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing ...

Molecular ESR1 changes may signal symptomatic progression before imaging in metastatic breast cancer, supporting camizestrant for improved quality of life.

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

Metastatic disease of the liver accounts for the vast majority of detected liver masses. In patients with suspected metastatic disease, cross-sectional imaging with ultrasound (US), computed ...

In this exclusive MedPage Today video, Specht is joined via Zoom by study co-lead, Heather Jacene, MD, of Brigham and Women's ...

In this analysis of colorectal cancer patients from 2 clinical trials, researchers aimed to assess the effect of physical activity on overall survival.

A set of 4,522 computed tomography (CT) reports of 550 patients with 14 types of cancer was used to fine-tune four clinical large language models (LLMs) for multilabel classification of metastatic ...

The Center for Metastasis Research eXcellence (MET-X) is an interdisciplinary and collaborative program at Fred Hutch Cancer Center focused on one of the most challenging areas of cancer biology: ...

The FDA approved fam-trastuzumab derextecan-nki (Enhertu; Daiichi Sankyo, Inc), a HER2-directed antibody-drug conjugate (ADC), in combination with pertuzumab as a first-line treatment for patients ...